Abstract 2978
Background
Cancer and diabetes are prevalent diseases worldwide. The purpose of this study was to assess quality of life and the factors influence it in the individuals with coexistence diabetes type 2 and cancer.
Methods
A cross-sectional study was conducted in a large hospital in a major Greek city. Convenience sample of 101 patients with cancer and diabetes type 2 undergoing chemotherapy constituted the study group. Quality of life was measured by the Audit of Diabetes Depedent-QoL-Questionnaire (ADDQoL-19). Information on social-demographic, treatment of tumors and diabetes, and other clinical characteristics were collected by other questionnaire. Descriptive statistics were used for demographic characteristics. For data that were not normally distributed, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis test) were applied.
Results
The majority of patients had cancer stage II (n = 52, 51,5%) and diabetes 2 for almost seven years. Individuals with coexistence of diabetes 2 and cancer reported that disease affected the overall quality of life (1.84±1.18). Also, there is a negative score in other subscale as freedom to eat (-1.43 ±0.80) and financial situation (-1.25±0,84). It was found that cancer’s stage influences the general quality of life domain (p = 0.023). Also, there were statistical significant differences between type of regimen for diabetes and several domains of quality of life. More particular, working life (p = 0.004), family life (p = 0.003), friendship and social life (p = 0.005), physical health (p = 0.003), leisure activities (p = 0.004) and financial situation (p = 0.004) are some of these domains that they are further influenced. Additionally the family status influences self-confidence (p = 0.001) and motivation (p = 0.007).
Conclusions
Taking all the above under consideration, we conclude that social-demographic and clinical characteristics were associated with quality of life in patients with cancer and diabetes 2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract